3o2m › Citations

Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.

Comess KM, Sun C, Abad-Zapatero C, Goedken ER, Gum RJ, Borhani DW, Argiriadi M, Groebe DR, Jia Y, Clampit JE, Haasch DL, Smith HT, Wang S, Song D, Coen ML, Cloutier TE, Tang H, Cheng X, Quinn C, Liu B, Xin Z, Liu G, Fry EH, Stoll V, Ng TI, Banach D, Marcotte D, Burns DJ, Calderwood DJ, Hajduk PJ
ACS Chem Biol 6 234-44 (2011)
Cited: 58 times
EuropePMC logo PMID: 21090814

Abstract

Inhibition of protein kinases has validated therapeutic utility for cancer, with at least seven kinase inhibitor drugs on the market. Protein kinase inhibition also has significant potential for a variety of other diseases, including diabetes, pain, cognition, and chronic inflammatory and immunologic diseases. However, as the vast majority of current approaches to kinase inhibition target the highly conserved ATP-binding site, the use of kinase inhibitors in treating nononcology diseases may require great selectivity for the target kinase. As protein kinases are signal transducers that are involved in binding to a variety of other proteins, targeting alternative, less conserved sites on the protein may provide an avenue for greater selectivity. Here we report an affinity-based, high-throughput screening technique that allows nonbiased interrogation of small molecule libraries for binding to all exposed sites on a protein surface. This approach was used to screen both the c-Jun N-terminal protein kinase Jnk-1 (involved in insulin signaling) and p38α (involved in the formation of TNFα and other cytokines). In addition to canonical ATP-site ligands, compounds were identified that bind to novel allosteric sites. The nature, biological relevance, and mode of binding of these ligands were extensively characterized using two-dimensional (1)H/(13)C NMR spectroscopy, protein X-ray crystallography, surface plasmon resonance, and direct enzymatic activity and activation cascade assays. Jnk-1 and p38α both belong to the MAP kinase family, and the allosteric ligands for both targets bind similarly on a ledge of the protein surface exposed by the MAP insertion present in the CMGC family of protein kinases and distant from the active site. Medicinal chemistry studies resulted in an improved Jnk-1 ligand able to increase adiponectin secretion in human adipocytes and increase insulin-induced protein kinase PKB phosphorylation in human hepatocytes, in similar fashion to Jnk-1 siRNA and to rosiglitazone treatment. Together, the data suggest that these new ligand series bind to a novel, allosteric, and physiologically relevant site and therefore represent a unique approach to identify kinase inhibitors.

Reviews - 3o2m mentioned but not cited (4)

  1. Computational insights for the discovery of non-ATP competitive inhibitors of MAP kinases. Schnieders MJ, Kaoud TS, Yan C, Dalby KN, Ren P. Curr. Pharm. Des. 18 1173-1185 (2012)
  2. Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families. Li L, Meyer C, Zhou ZW, Elmezayen A, Westover K. J Mol Biol 434 167626 (2022)
  3. C-Jun N-terminal kinase inhibitors: Structural insight into kinase-inhibitor complexes. Duong MTH, Lee JH, Ahn HC. Comput Struct Biotechnol J 18 1440-1457 (2020)
  4. Kinase Atlas: Druggability Analysis of Potential Allosteric Sites in Kinases. Yueh C, Rettenmaier J, Xia B, Hall DR, Alekseenko A, Porter KA, Barkovich K, Keseru G, Whitty A, Wells JA, Vajda S, Kozakov D. J. Med. Chem. 62 6512-6524 (2019)

Articles - 3o2m mentioned but not cited (15)

  1. Structural mechanisms of allostery and autoinhibition in JNK family kinases. Laughlin JD, Nwachukwu JC, Figuera-Losada M, Cherry L, Nettles KW, LoGrasso PV. Structure 20 2174-2184 (2012)
  2. Structural and functional analysis of the natural JNK1 inhibitor quercetagetin. Baek S, Kang NJ, Popowicz GM, Arciniega M, Jung SK, Byun S, Song NR, Heo YS, Kim BY, Lee HJ, Holak TA, Augustin M, Bode AM, Huber R, Dong Z, Lee KW. J. Mol. Biol. 425 411-423 (2013)
  3. Uncovering the Pharmacological Mechanism of Stemazole in the Treatment of Neurodegenerative Diseases Based on a Network Pharmacology Approach. Zhang J, Li H, Zhang Y, Zhao C, Zhu Y, Han M. Int J Mol Sci 21 E427 (2020)
  4. Alpha-Linolenic Acid Impedes Cadmium-Induced Oxidative Stress, Neuroinflammation, and Neurodegeneration in Mouse Brain. Alam SI, Kim MW, Shah FA, Saeed K, Ullah R, Kim MO. Cells 10 2274 (2021)
  5. Effect of Binding Pose and Modeled Structures on SVMGen and GlideScore Enrichment of Chemical Libraries. Xu D, Meroueh SO. J Chem Inf Model 56 1139-1151 (2016)
  6. Modeling of RAS complexes supports roles in cancer for less studied partners. Engin HB, Carlin D, Pratt D, Carter H. BMC Biophys 10 5 (2017)
  7. Ligand Binding Introduces Significant Allosteric Shifts in the Locations of Protein Fluctuations. Kumar A, Jernigan RL. Front Mol Biosci 8 733148 (2021)
  8. Network Pharmacology and Molecular Docking Study of Zhishi-Baizhu Herb Pair in the Treatment of Gastric Cancer. Qu Y, Yang X, Li J, Zhang S, Li S, Wang M, Zhou L, Wang Z, Lin Z, Yin Y, Liu J, Wang N, Yang Y. Evid Based Complement Alternat Med 2021 2311486 (2021)
  9. Biochanin A abrogates osteoclastogenesis in type 2 diabetic osteoporosis via regulating ROS/MAPK signaling pathway based on integrating molecular docking and experimental validation. He Q, Yang J, Chen W, Pan Z, Chen B, Zeng J, Zhang N, Lin Y, Chen C, Xiao J, Li M, Li S, Wang H, Chen P. BMC Complement Med Ther 24 24 (2024)
  10. Canagliflozin Delays Aging of HUVECs Induced by Palmitic Acid via the ROS/p38/JNK Pathway. Hao W, Shan W, Wan F, Luo J, Niu Y, Zhou J, Zhang Y, Xu N, Xie W. Antioxidants (Basel) 12 838 (2023)
  11. Computational Analysis of Crystallization Additives for the Identification of New Allosteric Sites. Fogha J, Diharce J, Obled A, Aci-Sèche S, Bonnet P. ACS Omega 5 2114-2122 (2020)
  12. Essential site scanning analysis: A new approach for detecting sites that modulate the dispersion of protein global motions. Kaynak BT, Bahar I, Doruker P. Comput Struct Biotechnol J 18 1577-1586 (2020)
  13. Mapping Molecular Networks within Clitoria ternatea Linn. against LPS-Induced Neuroinflammation in Microglial Cells, with Molecular Docking and In Vivo Toxicity Assessment in Zebrafish. Mat Zian NFA, Swain P, Mohd Faudzi SM, Zakaria N, Wan Ibrahim WN, Abu Bakar N, Shaari K, Stanslas J, Choi TI, Kim CH. Pharmaceuticals (Basel) 15 467 (2022)
  14. Novel method to identify group-specific non-catalytic pockets of human kinome for drug design. Wang H, Guan Z, Qiu J, Jia Y, Zeng C, Zhao Y. RSC Adv 10 2004-2015 (2020)
  15. Proposing the Promiscuous Protein Structures in JNK1 and JNK3 for Virtual Screening in Pursuit of Potential Leads. Sailapathi A, Murugan G, Somarathinam K, Gunalan S, Jagadeesan R, Yoosuf N, Kanagaraj S, Kothandan G. ACS Omega 5 3969-3978 (2020)


Reviews citing this publication (11)

  1. Ten things you should know about protein kinases: IUPHAR Review 14. Fabbro D, Cowan-Jacob SW, Moebitz H. Br. J. Pharmacol. 172 2675-2700 (2015)
  2. Targeted Protein Degradation by Small Molecules. Bondeson DP, Crews CM. Annu. Rev. Pharmacol. Toxicol. 57 107-123 (2017)
  3. Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease. Barnes PJ. Pharmacol. Rev. 68 788-815 (2016)
  4. Unbiased binding assays for discovering small-molecule probes and drugs. Kemp MM, Weïwer M, Koehler AN. Bioorg. Med. Chem. 20 1979-1989 (2012)
  5. Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges. Breen ME, Soellner MB. ACS Chem. Biol. 10 175-189 (2015)
  6. c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer's Diseases. Hepp Rehfeldt SC, Majolo F, Goettert MI, Laufer S. Int J Mol Sci 21 E9677 (2020)
  7. A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors. Astolfi A, Iraci N, Manfroni G, Barreca ML, Cecchetti V. ChemMedChem 10 957-969 (2015)
  8. A Comprehensive Structural Overview of p38α Mitogen-Activated Protein Kinase in Complex with ATP-Site and Non-ATP-Site Binders. Astolfi A, Manfroni G, Cecchetti V, Barreca ML. ChemMedChem 13 7-14 (2018)
  9. Drug discovery from natural products using affinity selection-mass spectrometry. Muchiri RN, van Breemen RB. Drug Discov Today Technol 40 59-63 (2021)
  10. Exploring new targets and chemical space with affinity selection-mass spectrometry. Prudent R, Annis DA, Dandliker PJ, Ortholand JY, Roche D. Nat Rev Chem 5 62-71 (2021)
  11. The protein kinase CK1: Inhibition, activation, and possible allosteric modulation. Sunkari YK, Meijer L, Flajolet M. Front Mol Biosci 9 916232 (2022)

Articles citing this publication (28)

  1. Biosensor-based small molecule fragment screening with biolayer interferometry. Wartchow CA, Podlaski F, Li S, Rowan K, Zhang X, Mark D, Huang KS. J. Comput. Aided Mol. Des. 25 669-676 (2011)
  2. Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases. Cowan-Jacob SW, Jahnke W, Knapp S. Future Med Chem 6 541-561 (2014)
  3. A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A. Martin MP, Zhu JY, Lawrence HR, Pireddu R, Luo Y, Alam R, Ozcan S, Sebti SM, Lawrence NJ, Schönbrunn E. ACS Chem. Biol. 7 698-706 (2012)
  4. Fluorophore labeled kinase detects ligands that bind within the MAPK insert of p38α kinase. Getlik M, Simard JR, Termathe M, Grütter C, Rabiller M, van Otterlo WA, Rauh D. PLoS ONE 7 e39713 (2012)
  5. From in Silico Discovery to intra-Cellular Activity: Targeting JNK-Protein Interactions with Small Molecules. Kaoud TS, Yan C, Mitra S, Tseng CC, Jose J, Taliaferro JM, Tuohetahuntila M, Devkota A, Sammons R, Park J, Park H, Shi Y, Hong J, Ren P, Dalby KN. ACS Med Chem Lett 3 721-725 (2012)
  6. A comparative study of fragment screening methods on the p38α kinase: new methods, new insights. Pollack SJ, Beyer KS, Lock C, Müller I, Sheppard D, Lipkin M, Hardick D, Blurton P, Leonard PM, Hubbard PA, Todd D, Richardson CM, Ahrens T, Baader M, Hafenbradl DO, Hilyard K, Bürli RW. J. Comput. Aided Mol. Des. 25 677-687 (2011)
  7. Biosensor-based approach to the identification of protein kinase ligands with dual-site modes of action. Navratilova I, Macdonald G, Robinson C, Hughes S, Mathias J, Phillips C, Cook A. J Biomol Screen 17 183-193 (2012)
  8. Deciphering the Arginine-binding preferences at the substrate-binding groove of Ser/Thr kinases by computational surface mapping. Ben-Shimon A, Niv MY. PLoS Comput. Biol. 7 e1002288 (2011)
  9. Selection of cyclic-peptide inhibitors targeting Aurora kinase A: problems and solutions. Shomin CD, Restituyo E, Cox KJ, Ghosh I. Bioorg. Med. Chem. 19 6743-6749 (2011)
  10. Letter A selective NMR probe to monitor the conformational transition from inactive to active kinase. Xie Q, Fulton DB, Andreotti AH. ACS Chem. Biol. 10 262-268 (2015)
  11. NMR spectroscopic investigations of the activated p38α mitogen-activated protein kinase. Nielsen G, Schwalbe H. Chembiochem 12 2599-2607 (2011)
  12. Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf. Samadani R, Zhang J, Brophy A, Oashi T, Priyakumar UD, Raman EP, St John FJ, Jung KY, Fletcher S, Pozharski E, MacKerell AD, Shapiro P. Biochem. J. 467 425-438 (2015)
  13. A fluorescence-based assay for p38α recruitment site binders: identification of rooperol as a novel p38α kinase inhibitor. Li J, Kaoud TS, LeVieux J, Gilbreath B, Moharana S, Dalby KN, Kerwin SM. Chembiochem 14 66-71 (2013)
  14. Polyphony: superposition independent methods for ensemble-based drug discovery. Pitt WR, Montalvão RW, Blundell TL. BMC Bioinformatics 15 324 (2014)
  15. Allosteric sites can be identified based on the residue-residue interaction energy difference. Ma X, Qi Y, Lai L. Proteins 83 1375-1384 (2015)
  16. Architecture of the MKK6-p38α complex defines the basis of MAPK specificity and activation. Juyoux P, Galdadas I, Gobbo D, von Velsen J, Pelosse M, Tully M, Vadas O, Gervasio FL, Pellegrini E, Bowler MW. Science 381 1217-1225 (2023)
  17. Proline Hydroxylation Primes Protein Kinases for Autophosphorylation and Activation. Lee SB, Ko A, Oh YT, Shi P, D'Angelo F, Frangaj B, Koller A, Chen EI, Cardozo T, Iavarone A, Lasorella A. Mol Cell 79 376-389.e8 (2020)
  18. The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region. Agnew C, Liu L, Liu S, Xu W, You L, Yeung W, Kannan N, Jablons D, Jura N. J. Biol. Chem. 294 13545-13559 (2019)
  19. Characterization of p38α autophosphorylation inhibitors that target the non-canonical activation pathway. González L, Díaz L, Pous J, Baginski B, Duran-Corbera A, Scarpa M, Brun-Heath I, Igea A, Martin-Malpartida P, Ruiz L, Pallara C, Esguerra M, Colizzi F, Mayor-Ruiz C, Biondi RM, Soliva R, Macias MJ, Orozco M, Nebreda AR. Nat Commun 14 3318 (2023)
  20. Design, Synthesis, and Biological Evaluation of Quercetagetin Analogues as JNK1 Inhibitors. Hierold J, Baek S, Rieger R, Lim TG, Zakpur S, Arciniega M, Lee KW, Huber R, Tietze LF. Chemistry 21 16887-16894 (2015)
  21. Design, synthesis, and study of novel phenethyl-based antitumor phospholipids downregulating p38 mitogen-activated protein kinase. Hassan AHE, Oh YI, Lee CH, Kim YJ, Cho SB, Alam MM, Park SE, Chung KS, Lee KT, Lee YS. J Enzyme Inhib Med Chem 38 2217695 (2023)
  22. Development of WEE2 kinase inhibitors as novel non-hormonal female contraceptives that target meiosis†. Hanna CB, Mudaliar D, John K, Allen CL, Sun L, Hawkinson JE, Schönbrunn E, Georg GI, Jensen JT. Biol Reprod 103 368-377 (2020)
  23. HKPocket: human kinase pocket database for drug design. Wang H, Qiu J, Liu H, Xu Y, Jia Y, Zhao Y. BMC Bioinformatics 20 617 (2019)
  24. Identification and Inhibition of the Druggable Allosteric Site of SARS-CoV-2 NSP10/NSP16 Methyltransferase through Computational Approaches. Faisal S, Badshah SL, Kubra B, Sharaf M, Emwas AH, Jaremko M, Abdalla M. Molecules 27 5241 (2022)
  25. Identification of highly selective type II kinase inhibitors with chiral peptidomimetic tails. Han SJ, Jung JE, Oh DH, Kim M, Kim JM, Chung KS, Han HS, Lee JH, Lee KT, Jeong HJ, Park IH, Jeon E, Shin JS, Hwang D, Cho AE, Lee DH, Sim T. J Enzyme Inhib Med Chem 37 1257-1277 (2022)
  26. Selective Recognition of a Single HIV-1 G-Quadruplex by Ultrafast Small-Molecule Screening. Scalabrin M, Nadai M, Tassinari M, Lago S, Doria F, Frasson I, Freccero M, Richter SN. Anal Chem 93 15243-15252 (2021)
  27. Structure-based design, synthesis and crystallization of 2-arylquinazolines as lipid pocket ligands of p38α MAPK. Bührmann M, Wiedemann BM, Müller MP, Hardick J, Ecke M, Rauh D. PLoS ONE 12 e0184627 (2017)
  28. Targeting the non-ATP-binding pocket of the MAP kinase p38γ mediates a novel mechanism of cytotoxicity in cutaneous T-cell lymphoma (CTCL). Zhang XH, Chen CH, Li H, Hsiang J, Wu X, Hu W, Horne D, Nam S, Shively J, Rosen ST. FEBS Lett 595 2570-2592 (2021)


Quick links